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Abstract The human immunodeWciency virus (HIV) had
spread unrecognized in the human population as sexually
transmitted disease and was Wnally identiWed by its disease
AIDS in 1981. Even after the isolation of the causative
agent in 1983, the burden and death rate of AIDS acceler-
ated worldwide especially in young people despite the con-
fection of new drugs capable to inhibit virus replication
since 1997. However, at least in industrialised countries,
this trend could be reversed by the introduction of combina-
tion therapy strategies. The design of new drugs is on
going; besides the inhibition of the three enzymes of HIV
for replication and maturation (reverse transcriptase, integr-
ase and protease), further drugs inhibits fusion of viral and
cellular membranes and virus maturation. On the other
hand, viral diagnostics had been considerably improved
since the emergence of HIV. There was a need to identify
infected people correctly, to follow up the course of
immune reconstitution of patients by measuring viral load
and CD4 cells, and to analyse drug escape mutations lead-
ing to drug resistance. Both the development of drugs and
the reWned diagnostics have been transferred to the treat-
ment of patients infected with hepatitis B virus (HBV) and
hepatitis C virus (HCV). This progress is not completed;
there are beneWcial aspects in the response of the scientiWc
community to the HIV burden for the management of other
viral diseases. These aspects are described in this contribu-
tion. Further aspects as handling a stigmatising disease,
education of self-responsiveness within sexual relation-
ships, and ways for confection of a protective vaccine are
not covered.
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Introduction
The human immunodeWciency virus (HIV) was isolated in
1983 for the Wrst time just 2 years after the description of a
new disease aVecting especially young homosexually
active men [1]; originally it has been named lymphadenop-
athy associated virus (LAV) [2] and human T lymphotropic
virus type III (HTLV-III) [3], or got other names as AIDS
related virus (ARV) [4]. HIV is a member of the lentivi-
ruses within the retrovirus family. Lentiviruses are preva-
lent in plenty mammalian species as horse (equine
infectious anaemia virus), sheep (visna maedi virus), cattle
(bovine immunodeWciency virus), cat (feline immunodeW-
ciency virus), and Wnally in nearly all monkey species (sim-
ian immunodeWciency virus, SIV). Naturally, monkeys
living in Africa, Asia and South America are infected with
the simian T leukaemia virus (STLV) while lentivirus
infected monkeys are only found in Africa [5], indicating
that in terms of viral evolution, HIV is younger than the
related retrovirus STLV/HTLV. Monkeys infected with
SIV, which is endogenous in that species, will not develop
immunodeWciency; in contrast, SIV transmitted within
monkey species can lead to an acute illness associated with
immunodeWciency and AIDS like symptoms [6, 7].
HIV is divided into two types, HIV-1 and HIV-2. HIV-1
consists of the groups M, N and O, HIV-2 of the groups A
to G, which were formerly named subtypes. On the molecu-
lar basis, HIV-1 group M is nearly identical to SIVcpz,
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virus clades that are found in chimpanzees (Pan troglo-
dytes) in Central Africa, and HIV-1 group O viruses have
been detected in the faeces of three wild living gorillas in
Cameroon [8], while HIV-2 is identical to SIV from sooty
mangabey monkeys (Cercopithecus atys—SIV smm) [5]. It
seems that in monkeys, host and virus have adapted over
time to equilibrium in such a way that the virus replicates to
high amounts, but no longer kills the host. In humans both
HIV-1 and HIV-2 cause immunodeWciency (AIDS); this
usually occurs in HIV-1 and HIV-2 infected but untreated
patients after 10 and 15 years, respectively. The lacking
pathogenicity in monkeys compared to the high pathoge-
nicity in humans and historical analyses showed an increase
of the anti-HIV seroprevalence in stored plasma samples in
Central-Africa between 1950 and 1970 [4, 9, 10] and the
lacking or low prevalence in pygmies in Cameroon [11] are
further arguments that HIV was introduced to humans only
‘recently’, most probably around the time of the beginning
of World War 2 or perhaps slightly earlier [12].
The heterogeneity of HIV is easily shown in group M,
which is most prevalent in the world and is subdivided into
the subtypes A–K; subtypes E and I are missing, because
these were Wnally identiWed as recombinant forms. Actually,
frequently circulating recombinant form viruses (CRF) are
classiWed in CRF01–CRF43 and U for unknown subtype [13,
14]; the actual list is available at http://www.hiv.lanl.gov/
content/sequence/HIV/CRFs/CRFs.html. A recombination
event occurs frequently when one cell is infected with two
HIV strains; it is assumed that one of 400 HIV secreted from
a double infected cell is a recombinant virus. As far as ana-
lysed, SIVcpz from chimpanzees is by itself a stable recom-
binant form, in which the gag and the pol gene region
originate from the red capped mangabey monkeys (Cercopi-
thecus torquatus) SIV, and the env gene region from the
white nose or greater spot nose monkeys (Cercopithecus
nictitans) SIV [15–17]. The origin of the long terminal repeat
region (LTR) of the chimpanzee virus is still unclear. From
an evolutionary point of view, the diversiWcation of the chim-
panzee species in West Central Africa was driven by separa-
tion through the big rivers [16], leading to the development
of the species Pan troglodytes troglodytes, Pan t schweinfur-
thii in the Eastern Central part, and Pan t vellerosus in the
North-West Central part [17, 18], which might have hap-
pened around 100,000–200,000 years ago. All these species
actually carry a similar SIV, thus a recombinant virus might
have led to a stable infection in chimpanzees in ancient times
before further diversiWcation. All SIVcpz seem to be trans-
missible to humans.
The dynamic of HIV transmission is driven by two forces
leading to a worldwide spread: sexual intercourse and blood
contamination. The latter occurs now mostly by intravenous
drug consumption in the western world, and still by blood
transfusion in combination with a highly increasing HIV
incidence in developing countries. Before the beneWcial
period of antiretroviral treatment, most of the HIV infected
patients were dying with typical symptoms of AIDS caused
by opportunistic infections, neoplasia, marasmus associated
with diarrhoea and/or encephalopathy. This death rate in
young people was a tremendous stimulus to search for sub-
stances to improve antiretroviral therapy (ART), which
started in 1989 using zidovudine monotherapy, and became
suYciently eVective after the introduction of protease inhibi-
tors in 1996 (Table 1) resulting in the principle of highly
active antiretroviral therapy (HAART) [19].
The diagnostic task resulting from the spread of HIV was
to identify infected people as precisely as possible by reli-
able antibody tests and to monitor the status of patients by
laboratory methods. Laboratory markers like viral load and
CD4 cell count are useful to get information on the Wtness of
the virus and the residual power of the immune system,
respectively. Drug resistance determination was a prompt
step following ART, taking into account that the mutation
rate of HIV is relatively high with approximately 1 in
10,000, similar to that of plenty other RNA viruses [4, 10].
Improvement of diagnostics for HIV antibody, antigen 
and nucleic acid detection
HIV-antibody testing
In 1985, the Wrst HIV antibody ELISAs were available and
it was evident from the beginning that numerous test results
had been false positive, especially when testing pregnant
women. ConWrmatory tests were needed, which were based
on immunoXuorescence, since HIV could be grown nicely
on T-cell lines [20, 21], and western blot strips, which used
more or less highly puriWed antigenic material derived from
virus concentrated from supernatant of infected cells. A
consecutive procedure was the production of line immuno-
assays with antigenic material puriWed after cloning indi-
vidual HIV proteins (Fig. 1).
ELISA reWnement went through diVerent steps including
peptides as antigen, followed by using material from HIV-1
group M, group O and HIV-2 produced by recombinant
techniques, and switching from the indirect ELISA format
to the double antigen format, which allowed the simulta-
neous detection of IgM and IgG. Today’s tests are
combination tests, which detect HIV antibody and the p24-
antigen simultaneously [4, 22].
Detection of viral components by p24-antigen testing
To get information on the viral burden in AIDS patients, an
antigen assay was developed in the sandwich ELISA for-
mat using the core protein p24 in 1988; around 1,000 p24Med Microbiol Immunol (2009) 198:147–155 149
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molecules build up the conical core of one HIV particle. As
a result of the beneWt for the HIV diagnostic, a core-antigen
assay was developed for quantitative determination of HCV
in plasma 11 years later in 1999 [23, 24].
P24-antigen assays were very quickly replaced when
nucleic acid testing allowed the quantitative determination
of the HIV-RNA viral load in plasma. In addition, it
became evident that p24-antigen and viral load did not cor-
relate, since p24 is shed in huge amounts from the surface
of some infected cells [25].
Viral load tested by nucleic acid testing (NAT)
DiVerent methods have been applied for HIV-1 nucleic acid
detection such as PCR, NASBA, TMA, b-DNA, and Wnally
Taqman-PCR as a further reWnement [26]. The commer-
cially available tests have high sensitivity and high
throughput performance, and are not only used to monitor
patients, but also to increase safety of the blood supply by
the ability to detect HIV-RNA during early seroconversion
[27, 28]. To reach a high sensitivity, concentration of HIV
by ultracentrifugation was introduced as routine analysis.
Taken together, strategies and experiences made in HIV
testing had been transferred to other infectious agents: to
hepatitis C virus (HCV) concerning immunoblot as line
immunoassay, core antigen detection and nucleic acid test-
ing, as well as to hepatitis B virus (HBV) concerning viral
load quantiWcation and drug resistance determination
(Fig. 1). Additionally, experience gained from HIV has been
transferred to the diagnostics of EBV, CMV, and further
viruses, to bacteria as Borrelia, Treponema pallidum, to Tox-
oplasma and further infectious agents concerning conWrma-
tion of ELISA or agglutination test reactivity by immunoblot.
Nucleic acid testing has nearly completely replaced virus iso-
lation for all viruses and older methods of virus detection like
immunoXuorescence microscopy or antigen assays, since
NAT is faster, more sensitive and even cheaper.
Drug resistance testing
HIV has a high mutation rate due to the inWdelity of the
reverse transcriptase. Because of a not fully suppressive
ART, HIV mutants are selected which replicate in the
presence of the drug; hence, the drug is bound insuYciently
to the enzyme. The interaction of the drug and the corre-
sponding enzyme is associated with deWned amino acids
(key amino acids); both the wild type and the respective
mutant could be identiWed by nucleic acid sequencing of
the respective viral gene [29]. Generally, two methods,
phenotypic and genotypic testing, are available; for several
Fig. 1 Scheme of the algorithm of antibody, antigen and viral nucleic
acid testing in the diagnostics of HIV, HCV and HBV infection. When
the diagnostic window is closed and the initial antibody testing result
is negative virus infection is excluded, therefore further data are not
documented in the algorithm. When patients have to be treated depen-
dent predominantly on their clinical status, which is not cited in this
scheme, a circle of drug application, drug resistance testing and viral
load and CD4 cells determination in HIV infected patients, and viral
load and liver enzyme testing, as ALT and AST, in hepatitis patients
has to be pursued. Permanent treatment is obligatory in AIDS patients
and treatment in hepatitis patients occurs until improvement or Wnal
failure is obvious150 Med Microbiol Immunol (2009) 198:147–155
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reasons genotypic testing, which is based on nucleic acid
sequencing, is more favourable.
Drug resistance testing has now been introduced to HBV
and HCV diagnostics (Fig. 1) and will be extended further to
those viral diseases which are treatable with eVective antivi-
ral substances, such as neuraminidase inhibitors for inXu-
enza virus A and B especially concerning H5N1 [30, 31].
Resistance testing is still of minor value for viruses that are
permanently hidden in human cells such as herpes virus.
A further step forward was prediction of drug suscepti-
bility by resistance determination before starting treatment.
Analysis of subtype and genotype was based on the experi-
ence gathered by HPV [31]. Routine genotype analysis has
been extended now to HIV, HBV and HCV, and Wnally is
used for epidemiological studies of rota-, noro-, adeno-,
measles-virus, and other viruses [32, 33].
In this sense, methods introduced in routine HIV diagnos-
tics did smoothen the way for other infectious agents resulting
in a signiWcant beneWt for treating and monitoring patients.
Improvement of antiretroviral therapy and designing 
new drugs
Drug design for inhibition of virus replication started after
successful application of acyclovir and its inhibition of the
HSV polymerase (thymidine kinase), which was extend
later to beta-herpes virus as cytomegalovirus (CMV) with
ganciclovir [34]. SuVering and death of AIDS patients on
the one hand and knowledge of the structure of the virus
particle, replication cycle and three-dimensional conWgura-
tion of the enzymes on the other hand were a driving force
for the design of drugs able to inhibit viral growth and thus
reduce the pathogenic action of HIV [35].
HIV reverse transcriptase (RT)
The enzyme transcribes viral RNA in viral DNA, which is
incorporated into the human cell genome by the action of
the viral integrase. The Wrst drug applied for RT inhibition
was azidothymidine/zidovudine (AZT) (Table 1), a nucleo-
side analogue that leads to chain termination of the newly
synthesized DNA strand after incorporation. The whole
class was named nucleoside reverse transcriptase inhibitors
(NRTI). Other substances belonging to the NRTIs are did-
anosine (ddI), zalcitabine (ddC; no longer distributed),
stavudine (d4T), lamivudine (3TC), emtricitabine (FTC),
and abacavir (ABC) (Table 1). To avoid rapid selection of
resistant viruses, the combination of appropriate drugs for
treatment is necessary—this lesson was learned within the
Wrst year of antiretroviral therapy [19, 35].
Inhibition of the enzyme by non-nucleoside reverse
transcriptase inhibitors (NNRTI) was a consequence of the
exact mapping of the three-dimensional structure of the
reverse transcriptase including the RNase H domain. Pres-
ently used drugs are efavirenz (EFV), nevirapine (NVP),
etravirine (ETR), and to a smaller extent delavirdine (DLV)
(Table 1). Although the NNRTIs are potent drugs in antiret-
roviral combination treatment, they have a relatively low
genetic barrier, which means a rapid selection of drug resis-
tance associated mutations under non-suppressive ART;
except for ETR only one amino acid mutation is suYcient
to cause complete resistance.
A further step to RT inhibition was the introduction of
tenofovir disoproxil fumarate (TDF) a nucleotide reverse trans-
criptase inhibitor (NtRTI) in 2001. In contrast to the above-
mentioned NRTIs, TDF is already monophosphorylated, thus
it is activated avoiding the Wrst phosphorylation step [35].
One major message learned from treating HIV infected
patients was that besides the knowledge of the action of the
drugs, patient’s compliance, adherence and Wdelity to the
drug administration scheme was highly important for eVec-
tiveness of treatment; for example, a once daily is favour-
able to a twice daily administration.
HBV polymerase
Knowledge of drug interference with the HIV-RT was
transferred to HBV. Second DNA strand synthesis comple-
tion of HBV can be inhibited by substances known from
HIV therapy like 3TC, FTC, and TDF as well as by drugs
approved only for HBV treatment like adefovir, entecavir,
and telbivudine (Table 1) [36]. All these drugs act within
the active enzyme pocket of the HBV polymerase, which
contains among other amino acids the motif YMDDV
(YMDDL in HIV). Treatment of chronic HBV infection
has been considerably improved by the HIV antiretrovirals.
Since drug dosage is lower in HBV treatment compared to
HIV treatment, side eVects are smaller, and thus therapy is
more easily accepted by the patient. Studies on combina-
tion therapy of the cited drugs are under way, and a further
improvement is expected [37].
As observed in the genome of HIV, mutations within the
genome of HBV resulting in drug resistance were selected
during insuYcient treatment, too. For example, mutations
at positions rtL180 and rtM204, the latter located in the
YMDDV motif, were selected after 3TC treatment [36].
However, mutations in HBV occur later than in HIV since
the genome is circular with overlapping reading frames,
and therefore mutations in the HBV DNA–RNA polymer-
ase have to be tolerated in the HBV core protein as well.
Inhibition of the HCV replicase
The enzyme responsible for HCV replication is an RNA
dependent RNA polymerase encoded from the NS5B geneMed Microbiol Immunol (2009) 198:147–155 151
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region. Substances named nucleoside based RNA replicase
inhibitors (NRRI) have been designed, for example, valopi-
citabine, 2-O-methylcytidine, 2-C-methylcytidine, and 2-C-
methylguanosine [34]. First clinical trials showed that
administration of valopicitabine reduced the HCV viral
load by 1.2 log10 after 2 weeks. Additionally, non-nucleo-
side RNA replicase inhibitors (NNRRI) have been con-
fected; however, benzimidazole-5-carboxyamide and
indol-N-acetamide derivatives are currently not applicable
due to their toxicity [35, 38].
HIV Protease (PR)
The HIV PR monomer is a molecule consisting of 99 amino
acids. The Wrst protease inhibitors (PI) became broadly
available in 1997, after the three-dimensional structure of
the dimer forming molecule of the PR was elucidated
(Table 1). Chemical conWgurations of substances have been
designed, with the background that most of the human pro-
teases are serine-proteases while the HIV PR is an aspartate
protease. Drugs like saquinavir (SQV), indinavir (IDV),
nelWnavir (NFV), ritonavir (RTV), fos-amprenavir (FPV),
lopinavir (LPV), atazanavir (ATZ), tipranavir (TPV), and
darunavir (DRV) are currently available (Table 1). Admin-
istration of these substances in combination with RT inhibi-
tors led to a sustained and profound decline of the viral load
in treated patients [4, 19].
Three additional items have been learned from treatment
with protease inhibitors (PRI). The inhibition of the cyto-
chrome oxidase system P450 (CYP 3A4) by PRIs, but
especially by RTV, blocks the decomposition of the
enzyme and thus prolongs the half-life of some drugs,
while it does not interfere with the elimination of others.
Based on this observation, most of the PRIs are combined
Table 1 Time scale of the availability of antiviral drugs for the treatment against HIV, HBV and HCV
a Interferon delays virus particle production in the cell and alters the immune response, but is not involved in the inhibition of the action of the
polymerase (HBV, HCV) or protease (HCV)
Year HIV and enzyme inhibited HBV and polymerase inhibitor HCV
1965 Australia antigen
1983 HIV-1 isolated
1987 Zidovudine (RT)
1989 HCV, identiWed by its genome 
sequence interferon  for treatmenta
1991 Didanosine (RT)
1992 Zalcitabine (RT) Interferon a
1995 Stavudine (RT)
Saquinavir (PR)
1996 Nevirapine (RT)
Indinavir (PR)
Ritonavir (RT)
1997 NelWnavir (PR)
1998 Lamivudine (RT) Interferon  + ribavirin
1999 Abacavir (RT)
Amprenavir (PR)
Delavirdine (RT)
2000 Lopinavir + ritonavir (PR) Lamivudine
2001 Tenofovir (RT) Pegylated interferon  + ribavirin
2003 Emtricitabine (RT)
Atazanavir (PR)
Fosamprenavir (PR)
Enfurtide (gp41)
Adefovir NS3 protease inhibitor 
BILN2061 acts in vitro
2005 Tripanavir (PR) Pegylated interferon 
2006 Darunavir (PR)
2007 Maraviroc (CCR5) Entecavir
Telbivudine
2008 Raltegravir (IN)
Etravirine (RT)
Tenofovir
2009 ? Vicriviroc (CCR5)
Elvitegravir (IN)
Rilpivirine (RT)
Clevudine Albinterferon -2b152 Med Microbiol Immunol (2009) 198:147–155
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with RTV to elevate the drug level and to enhance the inhi-
bition of the PR; consequently, RTV is currently used as a
pharmacokinetic booster only. As one example, NFV acts
without interference of the cytochrome oxidase system.
The second point learned was the induction of lipodys-
trophy. Although aspartate proteases are seldom in the
human body, interference of PRIs in genetically predis-
posed subjects leads to lipodystrophy. The syndrome is
associated with fat shrinkage on the extremities, and fat
accumulation on the neck, shoulders and the abdomen after
several months or even several years of treatment. This
kind of side eVect is individual, time dependent and some-
times irreversible [39]. Lipodystrophy is as well induced by
some NRTI and partially enhanced by the combination of
NRTI with PRI.
The third point is that the protease is a small molecule.
Some of the amino acid mutations caused by one PRI may
be associated with resistance to several other PRI, for
example, a point mutation at position 84 is associated with
resistance to IDV, RTV, and FPV. This observation led to
rapid development of new drugs like ATV, TPV, and DRV
(Table 1), which might be still active when some of the key
amino acids are mutated.
A further beneWt originating from the development of
PRI is the observation that RTV, NFV and SQV inhibit the
intracellular growth of Leishmania [40, 41].
Inhibition of the HCV protease
The success of a sustained viral load reduction by the intro-
duction of PRIs for treatment of HIV was the basis of
designing new protease inhibitors for HCV treatment, for
both the NS3/NS4A serine protease and the NS2/3 cysteine
protease, which cleave the polyprotein precursor. Active
substances are ciluprevir (BLIN 2061), which reduced the
viral load by 2–3 log10, telaprevir (VX-950), boceprevir
(SCH 503054) and SCH446211. Their clinical use is
reserved to ongoing studies. Key amino acid changes caus-
ing resistance are N168 for ciluprevir (discontinued in
2005), and V36, T54, R155, A156 and D168 for telaprevir
[38, 42]. Telaprevir can be combined with pegylated inter-
feron alpha to suppress HCV production to undetectable
levels [43, 44].
HIV integrase inhibitors
The integrase molecule consists of around 250 amino acids,
is highly conserved between HIV subtypes, and the enzyme
sticks to the HIV nucleic acid forming dimers and tetra-
mers. Besides an integrase activity, the protein exhibits an
exonuclease activity. Such an enzyme does not exist in
viruses like HBV and HCV and not in human cells. Cur-
rently, raltegravir (RAL) and elvitegravir (EVG) (Table 1)
have been evaluated in clinical studies [45], and RAL has
recently been approved. In contrast to EVG, which has to
be taken together with RTV, RAL is eliminated without
involvement of the cytochrome oxidase P450 system [46],
and until now, no severe side eVects have been reported in
clinical trials for both substances. As described above for
the NNRTIs, one amino acid mutation is linked to a signiW-
cant loss of antiviral activity; however, the genetic barrier
is not as low as for the NNRTIs. Key amino acid mutations
for RAL are located at positions Y143, Q148, and N155,
but are generally accompanied by secondary mutations
such as G140S, and E138A/K. The key amino acids caus-
ing resistance to EVG are T66I, E92Q, Q148 K/R, N155H,
and to a minor degree G140S, S147G, and Q148H. To pre-
serve the power of these drugs integrase inhibitors can only
be applied within an eVective combination therapy and they
are active against HIV-1 and HIV-2 [35, 45, 47, 48].
Viral entry—fusion inhibitors
To enter the human cell HIV attaches to the CD4 molecule
followed by coreceptor binding, and thus initiates the fusion
process. The Wrst steps are mediated by the envelope pro-
teins gp120 and gp41. The N-terminal part of gp41 forms a
bundle by its two heptad repeat domains (HR1 and HR2),
and the gp120 trimer forms a pore through which the hydro-
phobic N-terminal part of the gp41 trimer molecule inserts
into the lipid layer of the cell membrane. ConXuence of the
viral lipid envelope and the plasma membrane brings the
envelope-stripped viral particle to the cytoplasm and termi-
nates the fusion process. When 30-mer peptides, structurally
identical to the HR2 region, are attached to gp41, fusion is
no longer possible. Based on this knowledge, a 36 amino
acid peptide (T-20) was designed, which binds in part to the
HR2 domain. When administered to patients, T-20 is capa-
ble to reduce the viral load by 2–3 log10 [49].
A disadvantage of T-20 is that is has to be given paren-
terally. A further limitation is that single amino acid muta-
tions are suYcient for a signiWcant loss of activity such as
G36, V38, and Q40, and to a lesser extent N42, N43 and
L44, L45. The advantage is that T-20 acts independently of
all enzymes and thus can be applied to patients with RT and
PR resistant HIV, and that it has a low spectrum of side
eVects besides injection site reactions [49].
With the synthesis of T-20, it was shown that a theoreti-
cal principle after veriWcation in tissue culture led to a drug
applicable in humans, which might be used for other
viruses as well [35, 49].
Viral entry—CCR5 coreceptor antagonists
The chemokine receptors 4 (CXCR4) and 5 (CCR5) are
coreceptors for HIV after gp120 has bound to the CD4Med Microbiol Immunol (2009) 198:147–155 153
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molecule. A lymphotropic or syncytium inducing HIV will
bind to CXCR4 (so called X4 virus), and a macrophago-
tropic or non-syncytium inducing virus to CCR5 (R5).
Additionally, some viral strains can use both receptors
(dual tropic). By analysis of the CCR5-molecule, it was
found that in white Caucasians approximately 1% have a
homozygous deletion in their genome (delta 32) resulting
in the absence of the 7 membrane spanning G-protein on
the surface of lymphocytes. The general state of health of
these carriers was unaVected, but they were less suscepti-
ble to acquisition of R5-virus transmitted by sexual
contact [4].
One of the substances developed to interfere with bind-
ing of HIV to the CCR5 coreceptor has been approved for
ART at the end of 2007 (maraviroc), one further (vicirvi-
roc) is pending (Table 1). In clinical trials, the evaluation
of the antiviral eYcacy of maraviroc showed a 2.5 log10
viral load reduction in short term monotherapy [50].
During treatment, it became evident that in most cases a
shift of the viral tropism from R5 to X4 led to maraviroc
failure by selecting a few mutations within the V3-loop of
HIV-1; typical amino acid changes are acidic to neutral or
neutral to basic [35,  50,  51]. These X4 variants were
mainly present as minority species; however, in some
cases selection of initially undetectable X4 strains has
been observed [52, 53]. In addition, therapy failure with-
out a tropism shift has been reported in some patients due
to the selection of point mutations within the V3-loop
causing resistance to maraviroc instead of leading to a
tropism shift [54].
As mentioned above, the use of CCR5 inhibitors is lim-
ited to R5 viruses of the HIV-1 group M, and will not
inhibit binding of HIV-2. During the natural course of HIV
infection, X4 viruses Wnally dominate in AIDS patients,
thus CCR5 inhibitors should be used earlier in the course
of the disease. A phenotypic assay is generally used to
determine the coreceptor binding, and genotypic
approaches are currently evaluated. Until now, this unique
strategy for HIV growth inhibition has not been extended
for further viruses.
Maturation inhibitors
Cleavage of the gag/pol precursor protein of HIV-1 results
in the release of the core protein. The enclosed capsid pro-
tein initially has a molecular size of 25.000 (p25), which is
further cleaved into a smaller fragment (p24). This step can
be inhibited by bevirimat, so that p25 will not be cleaved;
in consequence the polymerization of p24 is prevented and
the conic core is not formed [55, 56]. As learned from the
mode of action of protease inhibitors, HIV released from
cells after treatment with bevirimat will not be infectious
[35].
Conclusions
While the knowledge of inhibition of some enzymes has
been transferred from HIV to HBV and HCV, the blockage
of adhesion of a virus by changing access to its receptor is
still an open Weld to be applied for other viruses. In the case
of HIV, it has been shown that inhibition of this step is
eVective and beneWcial for the clinical outcome of diseased
patients. Application of this strategy for further viruses is
pending. In summary, the knowledge gained from the diag-
nostics and treatment of HIV has fertilized the Weld of clin-
ically important viruses causing chronic disease such as
HBV and HCV, and of epidemiologically important viruses
such as inXuenza and Dengue fever virus, while the interac-
tion of interferons [57] is important for HCV [58], but has
never touched HIV basically and the area of small interfer-
ing RNA (si-RNA) is still a Weld to be evolved.
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